Schizophrenia and Psychosis Flashcards
Schizophrenia: Diagnostic criteria
- Presence of 2 or more symptoms for a significant portion of a month
- Delusions
- Hallucinations
- Disorganized speech
- Grossly disorganized catatonic behavior
- Negative symptoms
- Social/Occupational dysfunction
- Four phases: premorbid, prodromal, acute/psychotic, stable/residual
Premorbid phase of Schizophrenia
- Delayed motor milestones
- Poor scholastic performance
- Reduced concentration and motivation
- Passivity
- Depression, anxiety, irritability, anger
- Sleep disturbance
- Bedwetting/enuresis
- Social withdrawal and isolation
Prodromal phase of schizophrenia
- Marked peculiar behavior
- Inappropriate expression of feeling
- Speech difficult to follow
- Poverty of speech and thought
- Odd ideas and ideas of reference
- Feelings of unreality
- Suspiciousness
- Deterioration in role functioning
- Attenuated psychosis syndrome
Acute/Psychotic phase of schizophrenia
- Delusions
- Auditory hallucinations
- Disorganized thinking/speech, confusion, loose associations
- Disorganized behavior
- Regressed behavior
- Echopraxia/Mirroring
- Waxy flexibility
- Alteration in affect: dysphoria, lability
- Alteration in attention
- Problems in decision making/executive function: indecisiveness, lack of insight, impaired judgement, illogical or concrete thinking, loose associations, difficulty initiating actions
- Deteriorating relationship: paranoia, withdrawal, lack of personal hygiene, inappropriate social behavior
Stable/residual phase of schizophrenia
- Symptoms similar to prodromal
Schizophrenia: Predisposing factors
- 81% Heritability
- Children of 1 parent 13% risk; 2 parents 27-35% risk; sibling 9%-17%; twin 48%
- Urban/pollution
- Winter
- Maternal starvation/viral infections
- Delivery complications
- High fevers in early childhood
- Triggered by high exposure to psychosocial stressors
Schizophrenia: Neurobiology
- decreased brain volume, larger third ventricles, atrophy of frontal lobe, cerebellum, hippocampus, amygdala
- Decreased blood flow to the frontal cortex, over activity in the basal ganglia (limbic system)
- Abnormal dopamine, serotonin, glutamate, GABA activity
Schizophrenia: Types
- No longer used in the DSM 5
** Paranoid: Preoccupied with delusions and auditory hallucinations
** Disorganized: Disorganized speech and behavior with flat or inappropriate
affect
** Catatonic: Multiple movement and behavior symptoms
** Residual: 1 year absence or attenuation of positive symptoms, evidence of
at least one past psychotic episode, primarily presents with negative
signs/symptoms
Schizoaffective disorder
- A major mood episode concurrent with schizophrenia symptoms
- Period of delusion/hallucinations for at least 2 weeks without prominent mood symptoms
- Mood symptoms are present for a substantial period of illness
Schizophreniform disorder
- Schizophrenia episodes last between 1 and 6 months
* About 2/3 develop schizophrenia
Brief psychotic disorder
- Schizophrenia symptoms last between 1 day and 6 months with eventual return to full functioning
- Delusions, Hallucinations, Disorganized speech, Disorganized or Catatonic behavior
Delusional Disorder
- Non-bizarre delusions of at least a month’s duration
- Other criteria for schizophrenia never met
- Functioning not markedly impaired or obviously odd
Delusional Disorders: Types
- Erotomanic: patient believes another individual loves them
- Grandiose: Patient has unrecognized talent
- Jealous: Patient believes spouse in unfaithful
- Persecutory: Patients believes others are sabotaging him
- Somatic: Delusions related to bodily functions
- Mixed: No prominent theme
- Unspecified: no classification
Shared psychotic disorder (folie a deux)
- second person develops a similar delusion
- Second person may not entirely meet the criteria for a delusional disorder
- Categorized in the DSM 5 as “other specified spectrum and other psychotic disorder
Psychotic Disorder Rating Scales
- Brief Psychiatric Rating Scale (BPRS)
- Positive and Negative Symptoms Scale (PANSS)
- Scale for Assessment of Negative Symptoms (SANS)
- Scale for Assessment of Positive Symptoms (SAPS)
- Moller-Murphy Symtom Management Assessment tool II
Treatment Modalities for Psychotic Disorders
- Assertive community treatment: core services team, assertive outreach, long term relationship with primary provider
- Clubhouse: psychosocial rehabilitation
- CBT for 4-9 months
- Family services: 6-9 months
- Group therapy; Self-help and support groups
- Multisystemic therapy for youth: services at home and school
- Fairweather Lodge Model: clients move into a residence from the hospital and operate a business; group norms and peer support
- 3 Rs Psychiatric rehabilitation: Relapse, Recovery, Rehabilitation; 12 week psychoeducation
Schizophrenia: Smoking cessation
- High incidence and morbidity associated with smoking
- Clozapine correlates with lower smoking as it increases acetylcholine release which activates nicotinic receptors
- Cigarette smoking increases the activity of CYP 1 A2 enzymes thus decreasing concentrations of clozapine and olanzpaine
- Smoking also increases clearance of fluphenazine and haloperidol
Schizophrenia: Pharmacologic Management
- First choice for newly diagnosed is the atypical antipsychotics except for clozapine and olanzapine because of metabolic effects.
- Initial doses should be lower by 1/2
- Consider clozapine after two trials of other antipsychotics; serum levels need to reach 350 nanograms/ml
Atypical Antipsychotics: Pharmacological effects
- Antagonize 5-HT2 serotonin and D2, D3, and E4 receptors
- Effective for both positive and negative symptoms
- Lower incidence of EPS
- Side effects: sedation, orthostatic hypotension, weight gain, glucose dysfunction, sexual dysfunction, GI complaints, QT interval prolongation (nl. .4-.44)
Atypical Antipsychotics “PINES”
- Clozapine (Clozaril): agranulocytosis
- Olanzapine (Zyprexa) 5-20 mg /day; IM formulation
- Quetiapine (Seroquel) 150-600 mg/day: Potential for cataracts, FDA approved for bipolar depression
- Asenapine (Saphis)
Atypical Antipsychotics: “DONES”
- Respiridone (Resperdal) 2-6 mg/day: sexual dysfunction, EPS at high doses; IM form
- Ziprasidone (Geodon) 40-160 mg/day: low in weight gain, QT prolongation, take with food, IM form
- Paliperidone (Invega): IM
- Lurasidone (Latuda)
- Iloperidone (Fanapt)
Atypical Antipsychotics: “PIPS”
- Aripiprazole (Abilify) 15-30 mg/day: partial agonist of D2 and 5DT2a receptors, complete antagonist of 5HT2a receptor; IM available; orthostatic hypotension, anticholinergic, FDA indication for MDD adjunct
- Brexpiprazole (Rexulti): partial agonist D2, 5HT1a, Antagonist of 5HT2a
Antipsychotics: First generation
- Haloperidol (Haldol): 1-30 mg/day
- Fluphenazine (Prolixin): 0.5-40 mg/day
- Perphenazine (Trilafon): 8-64 mg /day
- Trifluoperazine (Stelazine): 1-40 mg/day
- Thiothixene (Navane): 2-30 mg/day
- Loxapine (Loxitane): 20-250 mg/day
- Molindone (Moban): 50-225 mg/day
- Act effectively on positive symptoms and agitation
- EPS and Tardive Dyskinesia
Extrapyramidal symptoms
- Dystonia
- Pseudoparkinsonism
- Bradykinesia
- Akathisia
- Assess for EPS every 6 months using Abnormal Involuntary Movement Scale (AIMS)
- Treat with anticholinergic meds: Benztropine (Cogentin), trihexyphenidyl (Artane); Dopaminergic agent amantadine (Symmetrel)
- Acute dystonia is life threatening, treated with IV or IM benadryl
Tardive Dyskinesia
- Lip smacking
- Sucking
- Tongue protrusion
- Athetoid movements
- Grimacing
- Eye-blinking
- Rocking
- Toe or finger tapping
- Strumming or pill rolling movements
Neuroleptic Syndrome
- Older antipsychotics more likely to cause: e.g. Fluphenazine (Prolixin) and Haloperidol (Haldo)
- Also caused by metoclopramide (Reglan), Prochlorperazine (compazine), Promethazine (Phenergan)
- High fever, muscle stiffness, diaphoresis, tachycardia, BP fluctuations
- Treat with Dantrolene (Dantrium) to treat muscle stiffness; or dopamine agonists amantadine (symmetrel); bromocriptine (parlodel)
Treatment for acute psychotic agitation
- oral Resperdal, Zyprexa, Haldol, Ativan, Valium
* IM Zyprexa, Geodon, Haldol, Ativan